Navigation Links
Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
Date:6/27/2011

PARSIPPANY, N.J., June 27, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that it has been included in the Russell 3000® Index following Russell Investments' reconstitution of its comprehensive set of U.S. and global equity indexes on June 24, 2011.

The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies representing approximately 98 percent of the investable U.S. equity market. According to Russell Investments, the Russell 3000 Index is constructed to provide a comprehensive, unbiased and stable barometer of the broad market and is completely reconstituted annually to ensure new and growing equities are reflected. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 also serves as the U.S. component to the Russell Global Index.

For more information or to view the full Russell 3000® Index, please visit http://www.russell.com/Indexes/.

About Pacira

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPARELâ„¢ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPARELâ„¢ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPARELâ„¢ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... , , ROSH ... of innovative solutions for the advanced chronic,wound management market, ... Food and Drug Administration (FDA) to market its new,SilverStream(TM) ... Over-the-Counter version of the SilverStream product. , ...
... , , , , ... NXTM ), a leading manufacturer of innovative dialysis products, ... and their partners will be embarking on a week-long, conventional ... The cruise, dubbed the "2010 Freedom Cruise: We,re Taking Home ...
Cached Medicine Technology:EnzySurge Receives FDA Approval for SilverStream(TM) Innovative Wound Management Solution 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 3Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 4
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
(Date:4/17/2014)... than 40 years away from a food shortage that ... to a top scientist at the U.S. Agency for ... food production will be limited on a global scale ... Dr. Fred Davies, senior science advisor for the agency,s ... politically destabilizing by 2050 as energy issues are today.", ...
(Date:4/17/2014)... TORONTO, April 17, 2014While 94 per cent of Canadians ... that screen newborns for a specific number of genetic ... willing to participate in screening that would sequence their ... prick test" in their first day or two of ... taken from their heels and tested for about five ...
(Date:4/17/2014)... whose work has transformed cancer care in Northern Ireland, ... Academy of Cancer Sciences., The Academy, which was launched ... distinguished oncologists and cancer researchers which aims to reduce ... , Professor Johnston, whose leadership has seen cancer survival ... the UK league table to near the top, has ...
(Date:4/17/2014)... research to be carried out into HIV and ... a paper in The Lancet Infectious Diseases ... in the department of Parasitology and researchers from ... of Cambridge and the Royal Veterinary College looked ... HIV/AIDS and schistosomiasis of children, and found that ...
Breaking Medicine News(10 mins):Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2
... Mich., May 8 A woman in the ... minutes, but finding,breast cancer at an early stage ... of the most important woman in all our ... KitchenAid" is celebrating,Mother,s Day by involving the culinary ...
... Hospital buildings can heal,according to the first comprehensive ... environment on child patients in health care settings. ... the,Physical Environment is produced by the National Association ... with the Center,for Health Design. Findings from the ...
... result of San Diego State,University,s interim suspension ... supports the decisions of our,member fraternities to ... parties accountable for their actions. The NIC, ... with our member organizations and San,Diego State ...
... Empire State Building. The,base camp of Mount Everest. And ... co-founder of Love Hope Strength Foundation, an,international charity hosting ... cancer centers worldwide., In March of 2000, James ... doctors gave him a 50% chance of survival but ...
... Oracle Healthcare,Acquisition Corp. (the "Company") (OTC Bulletin Board: ... dissolution of the Company and,its proposed plan of ... April 16, 2008, at the special meeting of ... announced, the Company has set May 7, 2008 ...
... Telehealth, using telecommunication technology to deliver health ... delivery and availability of health care services to ... patients who received a telehealth intervention from care ... compared to patients who received traditional care. , ...
Cached Medicine News:Health News:Celebrity Chefs and America's Restaurants Cook for the Cure This Mother's Day 2Health News:Celebrity Chefs and America's Restaurants Cook for the Cure This Mother's Day 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 4Health News:James Chippendale Climbs the Mountain of Life 2Health News:Oracle Healthcare Acquisition Corp. Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation 2Health News:Patients with chronic illness benefit from telehealth intervention 2
The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures....
The Shandon Finesse 315 low-cost precision microtome is ergonomically designed to consistently produce high quality routine paraffin sections without user strain or fatigue....
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
Medicine Products: